Skip to main content
    S

    Surgery Partners Inc (SGRY)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $26.85
    +0.06 (+0.22%)

    Market Cap: $3.53B

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Surgery Partners Inc (SGRY) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Surgery Partners (SGRY) has a market cap of $3.53B and an enterprise value of $6.23B. Its trailing P/E of 95.9x is above its 5-year median of 34.1x. Its net debt of $2.70B equals 76.57% of its market cap.

    Total Valuation

    Enterprise value is 76.57% above the market cap, as debt exceeds cash.

    Market Cap$3.53B
    Enterprise Value$6.23B
    Latest price (Nov 17, 2026)$26.85

    Key Dates

    The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 1, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.03% in the quarter ended Sep 30, 2026 and grew 1.06% a year over 2 years.

    Shares Outstanding128.87M
    Shares Change (YoY)+1.30%
    Shares Change (QoQ)+0.03%
    Share Count Growth (2Y CAGR)+1.06%

    Valuation Ratios

    Sales and book value multiples are 1.0x and 2.1x. Its year-end P/E ranged from 22.5x to 214.3x from 2016 to 2025.

    P/E Ratio95.9x
    Forward P/E66.2x
    P/S Ratio1.0x
    Forward P/S1.1x
    P/B Ratio2.1x
    P/FCF Ratio17.1x
    P/OCF Ratio12.7x
    PEG Ratio5.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 11.4x EBITDA and 30.4x free cash flow.

    EV / Earnings88.1x
    EV / Sales1.9x
    EV / EBITDA11.4x
    EV / EBIT17.1x
    EV / FCF30.4x

    Price Statistics

    The stock is up 75.72% over 52 weeks and trades 50.76% above its 50-day average.

    Beta (1Y)1.02
    52-Week Change+75.72%
    1-Month Change+82.53%
    3-Month Change+97.43%
    6-Month Change+96.13%
    5-Year Change-43.58%
    10-Year Change+44.16%
    Total Return (1Y)+75.72%
    Total Return (3Y CAGR)-5.91%
    Total Return (5Y CAGR)-11.43%
    Return vs SPY (1Y)+65.32%
    Max Drawdown (1Y)-34.00%
    Max Drawdown (3Y)-67.64%
    Sharpe Ratio (1Y)0.94
    Correlation with SPY (1Y)0.23
    50-Day Average$17.81
    200-Day Average$15.21
    52-Week Range$11.41 to $27.23
    RSI (14 Days)87.8
    Average Volume (20 Days)7.59M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.17x current liabilities, and total debt is 1.84x shareholder equity.

    Current Ratio2.17x
    Quick Ratio2.01x
    Debt / Equity1.84x
    Debt / EBITDA5.65x
    Debt / FCF15.07x

    Returns and Efficiency

    Return on invested capital is 6.10% over the last 12 months, against a 5-year average of 5.96%.

    Return on Equity (ROE)4.25%
    Return on Assets (ROA)1.00%
    Return on Invested Capital (ROIC)6.10%
    Return on Capital Employed (ROCE)5.55%
    ROE (5Y Average)4.83%
    ROA (5Y Average)1.16%
    ROIC (5Y Average)5.96%
    Asset Turnover0.45x
    Inventory Turnover9.43x
    Receivables Turnover6.20x
    Cash Conversion Cycle28 days

    Taxes

    Income tax took 20.83% of pretax income over the last 12 months.

    Income Tax (TTM)$18.60M
    Effective Tax Rate20.83%

    Scores

    SGRY has an Altman Z-Score of 1.12, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score1.12
    Altman Z ZoneDistress
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $3.36B over the last 12 months is up 2.19% from the 12 months before.

    Revenue$3.36B
    Revenue Growth (YoY)+2.19%
    Gross Profit$2.53B
    Operating Income$363.70M
    Pretax Income$89.30M
    Net Income$70.70M
    EBITDA$541.00M
    EBIT$363.70M
    Reported EPS (TTM)$0.28

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 23.55% of the $7.05B in total assets.

    Cash and Equivalents$354.50M
    Total Debt$3.06B
    Net Debt$2.70B
    Net Debt Per Share$20.96
    Working Capital$581.40M
    Shareholder Equity$1.66B
    Book Value Per Share$12.92
    Tangible Book Value-$2.98B
    Total Assets$7.05B
    Total Liabilities$3.79B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $75.10M of capital spending, operating cash flow left $202.80M of free cash flow.

    Operating Cash Flow$277.90M
    Capital Expenditures$75.10M
    Free Cash Flow$202.80M
    FCF Per Share$1.57
    Depreciation and Amortization$177.30M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 10.82%, against a 5-year average of 12.42%.

    Gross Margin75.26%
    Operating Margin10.82%
    Pretax Margin2.66%
    Net Margin2.10%
    EBITDA Margin16.10%
    EBIT Margin10.82%
    FCF Margin6.04%
    Gross Margin (5Y Average)46.31%
    Operating Margin (5Y Average)12.42%
    Net Margin (5Y Average)2.99%

    Growth

    Revenue grew 9.22% a year over 3 years, and EPS 52.38% a year.

    Revenue Growth (3Y CAGR)+9.22%
    Revenue Growth (5Y CAGR)+12.21%
    EPS Growth (3Y CAGR)+52.38%
    FCF Growth (3Y CAGR)+35.74%
    FCF Growth (5Y CAGR)-0.84%
    Operating Income Growth (3Y CAGR)+4.11%
    Book Value Per Share Growth (2Y CAGR)-7.68%

    Revenue and profit by year

    Dividends and Yields

    SGRY does not pay a dividend. Its free cash flow yield is 5.86%.

    Earnings Yield1.04%
    FCF Yield5.86%
    Shareholder Yield6.25%

    Peer Position

    Against 10 similar companies, SGRY has the highest P/E.

    P/E Ratio95.9x vs 22.7x median
    P/S Ratio1.0x vs 1.7x median
    ROIC6.10% vs 8.68% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.19% vs +11.02% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -6.06% and EPS growth at -34.05% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-6.06%
    EPS Growth Forecast (2Y CAGR)-34.05%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About SGRY

    What is SGRY's market cap?

    Surgery Partners has a market cap of $3.53B. Its enterprise value, which adds debt and subtracts cash, is $6.23B.

    What is SGRY's P/E ratio?

    Surgery Partners has a trailing P/E ratio of 95.9x and a forward P/E of 66.2x.

    How many shares of SGRY are outstanding?

    Surgery Partners has 128.87M shares outstanding. The count is up 1.30% from a year earlier.

    Does SGRY pay a dividend?

    No. Surgery Partners does not pay a dividend.

    How much debt does SGRY have?

    Surgery Partners has $3.06B of total debt and $354.50M of cash and equivalents, a net debt position of $2.70B.